|Bid||33.63 x 1100|
|Ask||33.64 x 1100|
|Day's Range||33.37 - 33.76|
|52 Week Range||24.10 - 46.62|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||12.94|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800 million in cash. SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases.
NEW YORK, NY / ACCESSWIRE / November 28, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE:BSX).
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1.